SG11201806401YA - G protein-coupled receptor (gpcr) modulation by imipridones - Google Patents

G protein-coupled receptor (gpcr) modulation by imipridones

Info

Publication number
SG11201806401YA
SG11201806401YA SG11201806401YA SG11201806401YA SG11201806401YA SG 11201806401Y A SG11201806401Y A SG 11201806401YA SG 11201806401Y A SG11201806401Y A SG 11201806401YA SG 11201806401Y A SG11201806401Y A SG 11201806401YA SG 11201806401Y A SG11201806401Y A SG 11201806401YA
Authority
SG
Singapore
Prior art keywords
international
pct
imipridones
modulation
protein
Prior art date
Application number
SG11201806401YA
Inventor
Joshua E Allen
Martin Stogniew
Varun Vijay Prabhu
Original Assignee
Oncoceutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/015817 external-priority patent/WO2016123571A1/en
Application filed by Oncoceutics Inc filed Critical Oncoceutics Inc
Publication of SG11201806401YA publication Critical patent/SG11201806401YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 3 August 2017 (03.08.2017) WIPO I PCT (10) International Publication Number WO 2017/132661 A3 11111111111111011101111111111101011111011111111011101111111111111011111111111110111111 (51) International Patent Classification: C07K 16/28 (2006.01) CO7D 401/04 (2006.01) C07K 14/705 (2006.01) CO7D 257/04 (2006.01) C07K 14/72 (2006.01) G01N 33/566 (2006.01) (21) International Application Number: PCT/US2017/015608 (22) International Filing Date: 30 January 2017 (30.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/US2016/015817 29 January 2016 (29.01.2016) 62/308,325 15 March 2016 (15.03.2016) 62/425,403 22 November 2016 (22.11.2016) (71) Applicant: ONCOCEUTICS, INC. [US/US]; 3624 Mar- ket Street, Suite 5E, Philadelphia, Pennsylvania 19104 (US). (72) Inventors: ALLEN, Joshua E.; 129 Tremont St, Cam- bridge, Massachusetts 02139 (US). STOGNIEW, Martin; 1870 Ferguson Lane, Blue Pell, Pennsylvania 19422 (US). PRABHU, Varun Vijay; 2375 Woodward St, Phil- adelphia, Pennsylvania 19115 (US). (74) Agents: PEARL COHEN ZEDEK LATZER BARATZ LLP et al.; 1500 Broadway, 12 Floor, New York, New York 10036 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Publ ished: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (88) Date of publication of the international search report: 31 August 2017 (84) US US US W O 20 17 / 13 266 1 A3 (54) Title: G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES (57) : Imipridones has been found to selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2- like subfamily of dopamine receptors, and to be useful for the treatment of conditions and disorders in need of such modulation, such as cancers, psychiatric disorders, and bacterial infections. In addition, methods of identifying whether a subject having these condition, is likely to be responsive to a treatment regimen, such as administration of an imipridone, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as administration of an imipridone, monitoring, or providing a prognosis for a subject with these condition are also provided.
SG11201806401YA 2016-01-29 2017-01-30 G protein-coupled receptor (gpcr) modulation by imipridones SG11201806401YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US2016/015817 WO2016123571A1 (en) 2015-01-30 2016-01-29 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy
US201662308325P 2016-03-15 2016-03-15
US201662425403P 2016-11-22 2016-11-22
PCT/US2017/015608 WO2017132661A2 (en) 2016-01-29 2017-01-30 G protein-coupled receptor (gpcr) modulation by imipridones

Publications (1)

Publication Number Publication Date
SG11201806401YA true SG11201806401YA (en) 2018-08-30

Family

ID=59398848

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201806401YA SG11201806401YA (en) 2016-01-29 2017-01-30 G protein-coupled receptor (gpcr) modulation by imipridones
SG10202108306UA SG10202108306UA (en) 2016-01-29 2017-01-30 G protein-coupled receptor (gpcr) modulation by imipridones

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202108306UA SG10202108306UA (en) 2016-01-29 2017-01-30 G protein-coupled receptor (gpcr) modulation by imipridones

Country Status (14)

Country Link
US (2) US11116771B2 (en)
EP (1) EP3408298A4 (en)
JP (2) JP7030701B2 (en)
KR (1) KR20180125460A (en)
CN (2) CN115844895A (en)
AU (2) AU2017211423B2 (en)
BR (1) BR112018015590A2 (en)
CA (1) CA3013044A1 (en)
IL (2) IL260815B (en)
MA (1) MA43879A (en)
MX (2) MX2018009227A (en)
NZ (1) NZ745425A (en)
SG (2) SG11201806401YA (en)
WO (1) WO2017132661A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172862B2 (en) * 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
WO2019055835A1 (en) * 2017-09-15 2019-03-21 The Regents Of The University Of California Detecting somatic single nucleotide variants from cell-free nucleic acid with application to minimal residual disease monitoring
US11674963B2 (en) 2017-09-27 2023-06-13 The Regents Of The University Of California GPCRs in cancer-associated fibroblasts
CA3089864A1 (en) 2018-01-31 2019-08-08 Mayo Foundation For Medical Education And Research Methods of treating fibrotic pathologies
CN112739332A (en) * 2018-04-09 2021-04-30 奥尔吉尼西丝公司 Bioparticle, redox, methods and compositions
CN109157656B (en) * 2018-10-15 2021-08-27 重庆医科大学附属永川医院 Double-target tumor vaccine and preparation method and application thereof
KR102403686B1 (en) 2020-05-15 2022-05-31 뉴로핏 주식회사 Apparatus and method for providing posion of brain stimulation
BR112023002082A2 (en) 2020-08-06 2023-05-09 Eoetvoes Lorand Tudomanyegyetem SYNTHESIS OF IMIPRIDONE DERIVATIVES AND THEIR EVALUATION FOR THEIR ANTI-CANCER ACTIVITY
CN112402439A (en) * 2020-11-18 2021-02-26 西安组织工程与再生医学研究所 Application of miR-325 nucleic acid analogue in preparation of products related to improvement of liver collagen deposition
US11648248B1 (en) 2022-01-12 2023-05-16 King Abdulaziz University Potent antimicrobial compounds with a pyridazine nucleus
CN115531378B (en) * 2022-10-19 2023-10-13 中国医学科学院医药生物技术研究所 Application of PHT427 as NDM-1 and KPC-2 dual inhibitor
CN116731136B (en) * 2023-08-04 2023-12-05 齐鲁工业大学(山东省科学院) Application of H3K23A histone point mutation in improving acetic acid tolerance and xylose fermentation performance of Saccharomyces cerevisiae

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2150062A1 (en) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo(1,2-a)pyrido(4,3-d)pyrimidines - withcns activity
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004082570A2 (en) 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2)
AU2004258147B2 (en) 2003-07-08 2009-04-30 State Of Queensland Acting Through Queensland Health Genetic marker of response to atypical antipsychotics and antidepressants and methods for use thereof
US8088895B2 (en) * 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
JP2010538798A (en) 2007-09-19 2010-12-16 オンコフルーア インコーポレイテッド Methods for imaging and treating organs and tissues
AU2012222812A1 (en) * 2011-02-28 2013-05-02 Mcmaster University Treatment of cancer with dopamine receptor antagonists
EP3679934A1 (en) 2011-04-29 2020-07-15 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
WO2015073072A1 (en) 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
NZ711948A (en) 2013-03-13 2020-02-28 Oncoceutics Inc Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
KR20240006008A (en) 2013-11-15 2024-01-12 온코슈틱스 인코포레이티드 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use
PT3125898T (en) 2014-03-31 2020-04-01 Scripps Research Inst Pharmacophore for trail induction
PL3250208T3 (en) * 2015-01-30 2021-04-06 Oncoceutics, Inc. 7-benzyl-4-(4-(trifluoromethyl)benzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4h)-one and salts thereof and their use in therapy
CN104860948B (en) * 2015-05-15 2017-09-26 南京盖特医药技术有限公司 Imidazopyrimidine ketone compounds and its preparation method and application
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas

Also Published As

Publication number Publication date
CN115844895A (en) 2023-03-28
KR20180125460A (en) 2018-11-23
JP2022046528A (en) 2022-03-23
AU2022200583B2 (en) 2024-05-02
MA43879A (en) 2018-12-05
SG10202108306UA (en) 2021-08-30
EP3408298A2 (en) 2018-12-05
US11116771B2 (en) 2021-09-14
AU2022200583A1 (en) 2022-02-24
AU2017211423A1 (en) 2018-09-06
MX2018009227A (en) 2018-11-09
BR112018015590A2 (en) 2019-10-01
IL260815B (en) 2021-10-31
US20220072001A1 (en) 2022-03-10
WO2017132661A2 (en) 2017-08-03
JP2019511460A (en) 2019-04-25
CA3013044A1 (en) 2017-08-03
CN109311980A (en) 2019-02-05
EP3408298A4 (en) 2019-09-04
AU2017211423B2 (en) 2021-10-28
NZ745425A (en) 2023-03-31
WO2017132661A3 (en) 2017-08-31
CN109311980B (en) 2023-01-17
MX2023004443A (en) 2023-05-08
IL286923A (en) 2021-10-31
JP7030701B2 (en) 2022-03-07
US20190307751A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
SG11201806401YA (en) G protein-coupled receptor (gpcr) modulation by imipridones
SG11201808990QA (en) Compositions for topical application of compounds
SG11201909949XA (en) Targeted immunotolerance
SG11201902938TA (en) Compounds, devices, and uses thereof
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201811491YA (en) Quinazoline and indole compounds to treat medical disorders
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201907023UA (en) Method of reducing neutropenia
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201805103VA (en) Method and system for service enablement
SG11201408385TA (en) Methods of detecting diseases or conditions
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201807250PA (en) Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
SG11201909224QA (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
SG11201807549TA (en) Combination of a cxcr4 antagonist and an immune checkpoint inhibitor
SG11201809882XA (en) Pharmaceutical combinations for treating cancer